Association between low expression levels of interleukin-9 and colon cancer progression

Huang,Yonghong; Cao,Yunfei; Zhang,Sen; Gao,Feng

doi:10.3892/etm.2015.2588

Association between low expression levels of interleukin-9 and colon cancer progression

Authors:
- Yonghong Huang
- Yunfei Cao
- Sen Zhang
- Feng Gao
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China, Department of Colorectal and Anal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: June 23, 2015 https://doi.org/10.3892/etm.2015.2588
Pages: 942-946
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although interleukin (IL)-9 has been extensively studied in inflammation and autoimmune diseases, the expression level of IL‑9 in colon cancer and its clinical significance are less well established. In total, 15 healthy donors (HDs) and 60 patients who had been diagnosed with colon cancer that had undergone a surgical resection were enrolled in the study. The plasma levels of IL‑9 in the HDs and cancer patients were detected by the liquid chip technique, while the expression levels of IL‑9 in the colon cancer tissues and normal tissues were analyzed using immunohistochemistry (IHC) and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Finally, the difference in the expression levels of IL‑9 between the patients classified as tumor‑node‑metastasis stage Ⅰ‑Ⅱ and stage Ⅲ‑Ⅳ was compared. The results demonstrated that the plasma levels of IL‑9 in the patients with colon cancer were significantly lower when compared with the HDs (1.29 vs. 2.53 pg/ml, P<0.05). Furthermore, according to the IHC and RT‑qPCR results, low expression levels of IL‑9 were observed in the colon cancer tissues when compared with the normal tissues (P<0.05). With regard to the plasma and tumor tissue samples, patients diagnosed with stage Ⅲ‑Ⅳ colon cancer expressed lower levels of IL‑9 compared with the stage Ⅰ‑Ⅱ patients (P<0.05). In conclusion, low expression levels of IL‑9 were observed in the tissue and plasma samples collected from the colon cancer patients, and the decreased expression of IL-9 was shown to correlate with colon cancer progression.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bindea G, Mlecnik B, Angell HK and Galon J: The immune landscape of human tumors: Implications for cancer immunotherapy. OncoImmunology. 3:e274562014. View Article : Google Scholar : PubMed/NCBI
4	Goswami R and Kaplan MH: A brief history of IL-9. J Immunol. 186:3283–3288. 2011. View Article : Google Scholar : PubMed/NCBI
5	Noelle RJ and Nowak EC: Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 10:683–687. 2010. View Article : Google Scholar : PubMed/NCBI
6	Demoulin JB and Renauld JC: Interleukin 9 and its receptor: an overview of structure and function. Int Rev Immunol. 16:345–364. 1998. View Article : Google Scholar : PubMed/NCBI
7	Kearley J, Erjefalt JS, Andersson C, et al: IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med. 183:865–875. 2011. View Article : Google Scholar : PubMed/NCBI
8	Steenwinckel V, Louahed J, Orabona C, et al: IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol. 178:3244–3251. 2007. View Article : Google Scholar : PubMed/NCBI
9	Oh CK, Raible D, Geba GP and Molfino NA: Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma. Inflamm Allergy Drug Targets. 10:180–186. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kim MS, Cho KA, Cho YJ and Woo SY: Effects of interleukin-9 blockade on chronic airway inflammation in murine asthma models. Allergy Asthma Immunol Res. 5:197–206. 2013. View Article : Google Scholar : PubMed/NCBI
11	Angkasekwinai P, Srimanote P, Wang YH, et al: Interleukin-25 (IL-25) promotes efficient protective immunity against Trichinella spiralis infection by enhancing the antigen-specific IL-9 response. Infect Immun. 81:3731–3741. 2013. View Article : Google Scholar : PubMed/NCBI
12	Khan WI, Richard M, Akiho H, et al: Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: Correlation with worm expulsion in murine nematode infections. Infect Immun. 71:2430–2438. 2003. View Article : Google Scholar : PubMed/NCBI
13	Li H and Rostami A: IL-9: Basic biology, signaling pathways in CD4⁺ T cells and implications for autoimmunity. J Neuroimmune Pharmacol. 5:198–209. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yang Y, Du L, Sun M, Kijlstra A and Yang P: IFN-beta inhibits the increased expression of IL-9 during experimental autoimmune uveoretinitis. PLoS One. 7:e485662012. View Article : Google Scholar : PubMed/NCBI
15	Leng RX, Pan HF, Ye DQ and Xu Y: Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Immunol. 1:28–32. 2012.PubMed/NCBI
16	Li H, Nourbakhsh B, Ciric B, Zhang GX and Rostami A: Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol. 185:4095–4100. 2010. View Article : Google Scholar : PubMed/NCBI
17	Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 18:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
18	Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J and Lustgarten J: Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother. 60:1775–1787. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sun GG, Wang YD, Cui DW, Cheng YJ and Hu WN: Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma. World J Gastroenterol. 20:4001–4010. 2014. View Article : Google Scholar : PubMed/NCBI
20	Cerkovnik P, Perhavec A, Zgajnar J and Novakovic S: Optimization of an RNA isolation procedure from plasma samples. Int J Mol Med. 20:293–300. 2007.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ouyang H, Shi Y, Liu Z, Feng S, et al: Increased interleukin-9 and CD4 +IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep. 7:1031–1037. 2013.PubMed/NCBI
23	de Vries VC, Wasiuk A, Bennett KA, et al: Mast cell degranulation breaks peripheral tolerance. Am J Transplant. 9:2270–2280. 2009. View Article : Google Scholar : PubMed/NCBI
24	Fábrega E, López-Hoyos M, San Segundo D, et al: Interleukin-9 in stable liver transplant recipients. Transplant Proc. 44:1536–1538. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Wang WD, Geng QR, et al: Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma. PLoS One. 9:e946372014. View Article : Google Scholar : PubMed/NCBI
26	Lv X, Feng L, Fang X, Jiang Y and Wang X: Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol. 6:911–916. 2013.PubMed/NCBI
27	Hamre H, Zeller B, Kanellopoulos A, et al: Serum cytokines and chronic fatigue in adults surviving after childhood leukemia and lymphoma. Brain Behav Immun. 30:80–87. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kobayashi H, Kumai T, Hayashi S, et al: A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. Cancer Immunol Immunother. 61:2215–2225. 2012. View Article : Google Scholar : PubMed/NCBI
29	Fischer M, Bijman M, Molin D, et al: Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia. 17:2513–2516. 2003. View Article : Google Scholar : PubMed/NCBI
30	Hornakova T, Staerk J, Royer Y, et al: Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem. 284:6773–6781. 2009. View Article : Google Scholar : PubMed/NCBI
31	Qiu L, Lai R, Lin Q, et al: Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK⁺ anaplastic large-cell lymphoma cells. Blood. 108:2407–2415. 2006. View Article : Google Scholar : PubMed/NCBI
32	Knoops L and Renauld JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors. 22:207–215. 2004. View Article : Google Scholar : PubMed/NCBI
33	Bauer JH, Liu KD, You Y, Lai SY and Goldsmith MA: Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis. J Biol Chem. 273:9255–9260. 1998. View Article : Google Scholar : PubMed/NCBI
34	Ye ZJ, Zhou Q, Yin W, Yuan ML, et al: Differentiation and immune regulation of IL-9-producing CD4⁺ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 186:1168–1179. 2012. View Article : Google Scholar : PubMed/NCBI
35	Lu Y, Hong S, Li H, et al: Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 122:4160–4171. 2012. View Article : Google Scholar : PubMed/NCBI
36	Tran E, Nielsen JS, Wick DA, et al: Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One. 5:e156252010. View Article : Google Scholar : PubMed/NCBI